Continuous coverage unwinding
Jun. 2023Important Notices
The continuous coverage unwinding period began on April 1. Medicaid recipients may have questions about their Medicaid eligibility determination.
We developed this FAQ to help you educate patients who have already submitted their renewal.
The goal of this material is to:
We developed this FAQ to help you educate patients who have already submitted their renewal.
The goal of this material is to:
- Help patients understand the Medicaid renewal process and have them keep an eye out for mail from DHS.
- Provide guidance to patients who did not return required verification documents.
- Provide guidance to patients who received a coverage termination letter.
- UPMC for You Continuous Coverage Postcard
- UPMC for You Continuous Coverage Postcard Spanish
- UPMC Community HealthChoices Participant Postcard
- UPMC Community HealthChoices Participant Postcard Spanish
In addition to the FAQ, the items below may be distributed to your UPMC for You patients and UPMC Community HealthChoices participants. These materials can be ordered through MarketingExpress, which is available via Provider OnLine.
Instructions on how to use MarketingExpress are also available. If you have any questions, please contact your physician account executive or call Provider Services at 1-866-918-1595.
Recent Announcements
Voluntary nationwide recall: Atorvastatin (Alkem – October)
Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.Nov. 2025Pharmacy Updates
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates